Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Stock Information for Q32 Bio Inc Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Q32 Bio Inc Com

Leap Therapeutics Reports First Quarter 2025 Financial Results
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study
Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.